



World Health
Organization

WORLD



AMR

AWARENESS WEEK

18-24 NOVEMBER

Save the date

HIV DRUG RESISTANCE WEBINAR


Monday 20 November 2023, 13:00-14:35 CET

[Click here to register in advance](#)



PREVENTING ANTIMICROBIAL
RESISTANCE TOGETHER

Report on the Global Action Plan on HIV Drug Resistance 2017-2021 and a future integrated Global Action Plan to prevent, monitor, and respond to drug-resistant HIV, viral hepatitis and sexually transmitted infections




Background

World Antimicrobial Resistance Awareness Week (WAAW) is a worldwide campaign that takes place every year to increase awareness and understanding of antimicrobial resistance. WAAW is organized by WHO's Antimicrobial Resistance Division (ARM). The campaign aims to promote best practices among the general public, One Health stakeholders, and policymakers, who all have a crucial role to play in preventing the emergence and spread of antimicrobial resistance. The Department of Global HIV, Hepatitis, and STI Programmes (HHS) has participated in WAAW since 2020 with the most relevant current HIV drug resistance topics.

In 2017, WHO published a five-year [Global Action Plan \(GAP\) on HIV drug resistance](#) (HIVDR) to address the public health impact of drug-resistant HIV. The GAP on HIVDR outlined a framework and interventions for countries and global stakeholders to prevent, monitor and respond to the emergence of drug-resistant HIV. The GAP timeframe concluded in 2021 and a [Report on the GAP 2017-2021](#) has been published. This webinar will review the impact of the GAP on HIVDR 2017-2021 and will present WHO's plan to develop an integrated GAP linking drug resistance prevention, monitoring, and response activities at all levels for HIV, viral hepatitis and sexually transmitted infections.

Agenda:



Time	Topic	Speaker/Facilitator
13:00-13:10	Opening remarks	Meg Doherty Director, Department of Global HIV, Hepatitis and STI Programmes, WHO Silvia Bertagnolio Unit Head, Control and Response Strategies, Antimicrobial Resistance Division, WHO
13:10-13:20	Report on the Global Action Plan (GAP) on HIV Drug resistance 2017-2021	Christopher Duncombe Department of Global HIV, Hepatitis and STI Programmes, WHO
	Successes and challenges as reported in the Report on the GAP 2017-2021 and potential future directions:	
13:20-13:30	<ul style="list-style-type: none">HIV drug resistance prevention and response	Elena Vovc Department of Global HIV, Hepatitis and STI Programmes, WHO
13:30-13:40	<ul style="list-style-type: none">HIV drug resistance monitoring and surveillance	Amalia Giron Department of Global HIV, Hepatitis and STI Programmes, WHO
13:40-13:50	<ul style="list-style-type: none">HIV drug resistance research priorities	Annemarie Wensing University Medical Center Utrecht, Netherlands
13:50-14:00	<ul style="list-style-type: none">Laboratory capacity for viral load and HIVDR testing in low- and middle-income countries	Kim Steegen National Health Laboratory Service, South Africa
14:00-14:10	<ul style="list-style-type: none">Governance, financing and enabling mechanisms	Eleanor Namusoke Magongo Ministry of Health, Uganda
14:10-14:20	Plans for an integrated Global Action Plan on drug resistance for HIV, viral hepatitis, and priority STIs for 2023–2030	Michael Jordan Department of Global HIV, Hepatitis and STI Programmes, WHO
14:20-14:30	Comments and Q&A	Dan Kuritzkes, Co-Moderator Brigham and Women’s Hospital, Boston, USA
14:30-14:35	Closing remarks	Eleanor Namusoke Magongo, Co-Moderator Ministry of Health, Uganda